However, this combination therapy upregulates TIGIT expression on CD8+ T cells, and the addition of anti‐TIGIT significantly enhances therapeutic efficacy, thus providing a novel triple‐drug strategy for MSS CRC. The gene discussed is CD8A; the disease is colorectal carcinoma.